Gates Foundation Pledges $120 Million to Help Get Covid Pills Quickly to Poor Countries
Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
View original article
Contributor: Stephanie Nolen
